It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The use of precision medicine for chemotherapy requires the individualization of the therapeutic regimen for each patient. This approach improves treatment efficacy and reduces the probability of administering ineffective drugs. To ensure accurate decision-making in a timely manner, anticancer drug efficacy tests must be performed within a short timeframe using a small number of cancer cells. These requirements can be satisfied via microfluidics-based drug screening platforms, which are composed of complex fluidic channels and closed systems. Owing to their complexity, skilled manipulation is required. In this study, we developed a microfluidic platform, to accurately perform multiple drug efficacy tests using a small number of cells, which can be conducted via simple manipulation. As it is a small, open-chamber system, a minimal number of cells could be loaded through simple pipetting. Furthermore, the extracellular matrix gel inside the chamber provides an in vivo-like environment that enables the localized delivery of the drugs to spontaneously diffuse from the channels underneath the chamber without a pump, thereby efficiently and robustly testing the efficacy and resistance of multiple drugs. We demonstrated that this platform enabled the rapid and facile testing of multiple drugs using a small number of cells (~ 10,000) over a short period of time (~ 2 days). These results provide the possibility of using this powerful platform for selecting therapeutic medication, developing new drugs, and delivering personalized medicine to patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Samsung Medical Center, Samsung Genome Institute, Seoul, South Korea (GRID:grid.414964.a) (ISNI:0000 0001 0640 5613)
2 Samsung Medical Center, Department of Breast Cancer Center, Seoul, South Korea (GRID:grid.414964.a) (ISNI:0000 0001 0640 5613)
3 Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Surgery, Seoul, South Korea (GRID:grid.414964.a); Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Department of Health Sciences and Technology, Seoul, South Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X)
4 Samsung Medical Center, Samsung Genome Institute, Seoul, South Korea (GRID:grid.414964.a) (ISNI:0000 0001 0640 5613); Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Department of Health Sciences and Technology, Seoul, South Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X); Sungkyunkwan University School of Medicine, Department of Molecular Cell Biology, Suwon, South Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X)




